Australia markets closed

BridgeBio Pharma, Inc. (BBIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.12+0.23 (+0.86%)
At close: 04:00PM EDT
27.12 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.07B
Enterprise value 6.28B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)20.98
Price/book (mrq)N/A
Enterprise value/revenue 28.72
Enterprise value/EBITDA -9.40

Trading information

Stock price history

Beta (5Y monthly) 1.06
52-week change 3-15.36%
S&P500 52-week change 324.16%
52-week high 344.32
52-week low 321.62
50-day moving average 327.41
200-day moving average 330.14

Share statistics

Avg vol (3-month) 31.97M
Avg vol (10-day) 31.98M
Shares outstanding 5187.13M
Implied shares outstanding 6190.33M
Float 8121.21M
% held by insiders 15.24%
% held by institutions 195.04%
Shares short (28 June 2024) 420M
Short ratio (28 June 2024) 47.25
Short % of float (28 June 2024) 416.50%
Short % of shares outstanding (28 June 2024) 410.69%
Shares short (prior month 31 May 2024) 416.63M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -246.23%
Operating margin (ttm)1.77%

Management effectiveness

Return on assets (ttm)-40.08%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)218.6M
Revenue per share (ttm)1.29
Quarterly revenue growth (yoy)11,461.90%
Gross profit (ttm)N/A
EBITDA -466.45M
Net income avi to common (ttm)-538.26M
Diluted EPS (ttm)-3.23
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)519.69M
Total cash per share (mrq)2.78
Total debt (mrq)1.73B
Total debt/equity (mrq)N/A
Current ratio (mrq)5.54
Book value per share (mrq)-5.61

Cash flow statement

Operating cash flow (ttm)-602.93M
Levered free cash flow (ttm)-382.72M